Skip to main content

Ligelizumab outperformed omalizumab for refractory chronic spontaneous urticaria

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Ligelizumab outperformed omalizumab for refractory chronic spontaneous urticaria

User login

Username

Password

Reset your password

Type	Lead	score